What is the Ristocetin Cofactor Assay (VWF:RCo)?
The ristocetin cofactor assay (VWF:RCo) is a laboratory test that measures the functional activity of von Willebrand factor (VWF) by assessing its ability to bind to platelet glycoprotein Ib (GPIb) in the presence of ristocetin, an antibiotic that facilitates this interaction. 1
Purpose and Clinical Context
The VWF:RCo assay serves as one of the essential diagnostic tests for von Willebrand disease (VWD), the most common inherited bleeding disorder. 1 No single laboratory test can diagnose VWD alone; the standard diagnostic approach requires:
- VWF antigen (VWF:Ag) - measures total VWF protein quantity 1
- VWF activity assay - measures functional platelet-binding ability of VWF 1
- Factor VIII activity (FVIII:C) - as VWF carries and protects factor VIII 1
How the Assay Works
The VWF:RCo assay uses intact platelets (native, formalin-fixed, or reconstituted lyophilized) combined with ristocetin to induce VWF-mediated platelet agglutination. 2 The degree of agglutination correlates with VWF functional activity. 3
Evolution of VWF:RCo Methodology
The assay has evolved through four generations:
- First generation (manual): Glass slide-based, laborious and operator-dependent 2
- Second generation (semi-automated): Adapted to traditional aggregometers with commercial reagents 2
- Third generation (fully automated): Adapted to automated coagulometers with improved precision 2
- Fourth generation (modified automated): Markedly improved sensitivity (limit of detection 3 IU/dL) with coefficient of variation 6-9% 2
Significant Limitations
Current VWD diagnosis guidelines now recommend newer assays over the traditional VWF:RCo assay due to multiple significant limitations: 1
- Poor reproducibility: Coefficient of variation up to 20-30% in semi-automated versions 2
- Low sensitivity: Cannot reliably measure VWF activity below 10-20 IU/dL, making it difficult to characterize severe VWD 2
- False low results: The D1472H VWF variant, present in approximately 63% of African Americans, causes falsely low VWF:RCo results 1
- Labor intensive: Particularly in earlier generation assays 2
Modern Alternatives
Newer assays using recombinant GPIb fragments have been developed to overcome VWF:RCo limitations and are now preferred: 1
- VWF:GPIbM assay: Uses recombinant mutated GPIb that binds VWF spontaneously without ristocetin 1
- VWF:GPIbR assay: Uses recombinant wild-type GPIb with ristocetin 1, 4
These newer assays offer superior precision, lower limits of detection (as low as 3-4% VWF), lower coefficient of variation (2-7%), and full automation. 4, 5, 6
Clinical Interpretation
The ratio of VWF activity to VWF antigen (VWF:RCo/VWF:Ag or VWF:GPIbR/VWF:Ag) is critical for VWD classification:
- Type 1 VWD: Proportional reduction in both VWF activity and antigen (ratio typically >0.6) 1
- Type 2 VWD: Disproportionately low VWF activity relative to antigen (ratio typically <0.6), indicating qualitative defects 1, 6
- Type 3 VWD: Virtually complete absence of VWF 1
Important Caveats
- The VWF:RCo assay historically represented the gold standard, so most clinical data correlating VWF levels with treatment responses (desmopressin, VWF concentrates) relate to VWF:RCo measurements. 2
- Different VWF activity assays show differential sensitivity to loss of high molecular weight VWF multimers, with VWF:RCo and collagen-binding assays demonstrating higher sensitivity than some newer mAb-based assays. 7
- The term "factor VIII ristocetin factor" is not standard nomenclature; the correct terminology is "VWF ristocetin cofactor activity" (VWF:RCo), which measures VWF function, not factor VIII directly. 1, 3